Blog

PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its subsidiary, Scilex Pharmaceuticals, Inc., (together, with...

30 Sep

Press Release

Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

July 15, 2021
Posted by Jitendra

PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in...

23 Sep

Press Release

Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

July 15, 2021
Posted by Jitendra

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially submitted a draft registration statement on Form S-1...

Characteristics of Analgesic Patch Formulations.

Draft Registration Statement

A Randomized, Open-Label, Bioequivalence Study of Lidocaine Topical System 1.8% and Lidocaine Patch 5% in Healthy Subjects

A Randomized, Crossover, Adhesion Performance and Pharamcokinetic Study of a Lidocaine Topical System Under Conditions of Water Exposure in Healthy Subjects.

Utility of lidocaine as a topical analgesic and improvements in patch delivery systems.

Treatment Patterns and Medication Use in Patients with Postherpetic Neuralgia

Scilex Announces New Medicaid Agreements with CA & FL

Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Scilex Semnur Corporate Presentation

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch